Once almost written-off, GSK’s Blenrep now looks like a practice-changing therapy for patients with relapsed/refractory multiple myeloma, after the company unveiled impressive Phase III overall survival data at the American Society of Hematology (ASH) meeting in San Diego, CA.
DREAMM Data Sets GSK’s Blenrep Up For Second Line Myeloma Dominance
Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.
